Trevi Therapeutics, Inc. (NASDAQ: TRVI) is a Healthcare company (Biotechnology) with a market capitalization of $2.2B. The Maz Rating grades it against the other companies in its sector.
About three months ago (July 2, 2026), Trevi Therapeutics, Inc. had a Maz Rating of 4.51 out of 5 (A, Strong Buy), ranked against the other companies in its sector. Its strongest factor then was Growth (4.65), among the strongest in its sector; its weakest was Valuation (1.15), among the most expensive in its sector. The other factors: Momentum 4.62 (among the strongest in its sector); Financial Health 4.26 (above most of its sector); Profitability 2.58 (around the middle of its sector). The current rating is for members: log in to see it.
At $15.31, Trevi Therapeutics, Inc. trades at 7.0x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -23.6%, return on invested capital of -18.5% and a free cash flow yield of -1.9%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 37.28. Over the past 52 weeks the share price ranged from $9.82 to $20.22, with a beta of 0.98.
Trevi Therapeutics, Inc. does not currently pay a dividend.
18 Wall Street analyst ratings cover the stock: 1 Strong Buy and 17 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.